1. Home
  2. UTHR vs GGG Comparison

UTHR vs GGG Comparison

Compare UTHR & GGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • GGG
  • Stock Information
  • Founded
  • UTHR 1996
  • GGG 1926
  • Country
  • UTHR United States
  • GGG United States
  • Employees
  • UTHR N/A
  • GGG N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • GGG Fluid Controls
  • Sector
  • UTHR Health Care
  • GGG Industrials
  • Exchange
  • UTHR Nasdaq
  • GGG Nasdaq
  • Market Cap
  • UTHR 13.4B
  • GGG 14.8B
  • IPO Year
  • UTHR 1999
  • GGG N/A
  • Fundamental
  • Price
  • UTHR $294.28
  • GGG $82.55
  • Analyst Decision
  • UTHR Buy
  • GGG Hold
  • Analyst Count
  • UTHR 13
  • GGG 3
  • Target Price
  • UTHR $379.69
  • GGG $89.00
  • AVG Volume (30 Days)
  • UTHR 547.4K
  • GGG 776.9K
  • Earning Date
  • UTHR 07-30-2025
  • GGG 07-23-2025
  • Dividend Yield
  • UTHR N/A
  • GGG 1.33%
  • EPS Growth
  • UTHR 17.94
  • GGG N/A
  • EPS
  • UTHR 25.63
  • GGG 2.82
  • Revenue
  • UTHR $3,077,800,000.00
  • GGG $2,167,974,000.00
  • Revenue This Year
  • UTHR $14.37
  • GGG $7.37
  • Revenue Next Year
  • UTHR $6.59
  • GGG $4.19
  • P/E Ratio
  • UTHR $11.48
  • GGG $29.29
  • Revenue Growth
  • UTHR 17.62
  • GGG 0.75
  • 52 Week Low
  • UTHR $266.98
  • GGG $72.06
  • 52 Week High
  • UTHR $417.82
  • GGG $92.86
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 49.57
  • GGG 35.24
  • Support Level
  • UTHR $272.12
  • GGG $82.39
  • Resistance Level
  • UTHR $307.71
  • GGG $88.00
  • Average True Range (ATR)
  • UTHR 8.47
  • GGG 1.57
  • MACD
  • UTHR -1.25
  • GGG -0.52
  • Stochastic Oscillator
  • UTHR 62.26
  • GGG 15.24

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About GGG Graco Inc.

Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.

Share on Social Networks: